Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

Amid the sultry summer months, a few signs of fall become apparent, such as the appearance of school supplies on stores ...

New analysis warns that suboptimal clinical trial designs and overreliance on surrogate markers may allow less effective flu ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="334655" class="cbxwpbkmarktrig ...